The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; 17 of the 31 sources its claims cite were checked for support.
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts
Open accessAbstract
Abstract Background Murine double minute 2 (MDM2) inhibitors reactivate wild-type p53 and are a promising therapy for glioblastoma, IDH-wildtype (GBM). Brigimadlin is a highly potent MDM2 inhibitor being tested in a phase 0/1 clinical trial in combination with radiation in GBM. Methods Brigimadlin pharmacokinetics, pharmacodynamics, and efficacy were evaluated in GBM patient-derived xenografts (PDXs). Results In vitro, brigimadlin impaired viability in TP53 wild-type GBM with an IC50 of 0.8-6.6 nmol/L, but sensitivity did not correlate with MDM2 amplification. In vivo, MDM2 amplification was highly correlated with efficacy. In subcutaneous PDXs, 1 or 2 mg/kg brigimadlin dosed weekly was highly effective in 2 MDM2-amplified PDXs. At 2 mg/kg, brigimadlin delayed tumor regrowth by >5-fold in the MDM2-amplified PDXs compared to 1.5-fold in a non-amplified PDX. In orthotopic PDXs, efficacy was more limited, but 2 mg/kg brigimadlin enhanced the response to fractionated radiation in MDM2-amplified PDXs. Consistent with blood-brain barrier efflux limiting drug distribution, 2 mg/kg brigimadlin extended survival by >5-fold in an MDM2-amplified orthotopic PDX established in Rag1−/−Abcb1a−/− Abcg2−/− mice. In pharmacodynamic studies, p53 target genes were upregulated at both subtherapeutic and therapeutic dose levels, and the extent of activation did not correlate with MDM2 status. Concentrations of brigimadlin in tumor tissue were approximately 10-fold higher in MDM2-amplified tumors, and intracellular drug levels directly correlated with drug-dependent MDM2 upregulation, suggesting target binding affects drug accumulation. Conclusions Brigimadlin is highly effective in MDM2-amplified GBM when adequate drug levels are achieved in tumor tissue. MDM2 amplification impacts both treatment efficacy and intratumoral drug accumulation.
Overview
CoChat Summary
TL;DR
Brigimadlin is highly effective in MDM2-amplified glioblastoma patient-derived xenografts when adequate intratumoral drug levels are achieved, but orthotopic efficacy is limited by blood-brain barrier efflux. MDM2 amplification is associated with both greater treatment efficacy and higher intratumoral brigimadlin accumulation.
Key findings
- In vitro, brigimadlin impaired viability in TP53 wild-type GBM lines with IC50 0.8–6.6 nmol/L, but sensitivity did not correlate with MDM2 amplification; the MDM4-amplified GBM8 line showed limited response and the TP53-mutant GBM120 line was highly resistant.
- In subcutaneous PDXs, 1 or 2 mg/kg weekly brigimadlin was highly effective in 2 MDM2-amplified PDXs; at 2 mg/kg, median time-to-endpoint was 80 days vs 15 days in GBM108 and 57 days vs 11 days in GBM143, compared with 12 days vs 8 days in non-amplified GBM14. Tumor-to-plasma ratios were 12.5 (GBM108), 5.8 (GBM143), and 0.71 (GBM14).
- In orthotopic GBM108, 2 mg/kg brigimadlin extended median survival to 56 days vs 41 days with vehicle; in efflux-deficient Rag1−/−Abcb1a−/−Abcg2−/− mice, 2 mg/kg extended survival beyond 365 days vs 70 days with vehicle, with brain-to-plasma ratio 0.38 vs 0.03 in nude mice.
- p53 target genes were upregulated at subtherapeutic and therapeutic doses, and the extent of activation did not correlate with MDM2 status; intratumoral brigimadlin concentrations were approximately 10-fold higher in MDM2-amplified tumors, and intracellular drug levels correlated with drug-dependent MDM2 upregulation.
Methods
- In vitro studies used short-term GBM PDX cultures; viability was measured after 7 days with brigimadlin 0–100 nmol/L by CellTiter-Glo 3D, with Western blot and qRT-PCR for p53 pathway markers and LC-MS/MS for intracellular drug levels.
- Subcutaneous and orthotopic PDX studies used athymic nude or double-knockout mice; brigimadlin was given weekly by oral gavage, with or without fractionated radiation (2 Gy × 10 fractions), and endpoints were tumor volume >3× initial or moribund.
- Drug concentrations in plasma, brain, and tumor were measured by LC-MS/MS; analyses included t-tests/rank-sum, 4-parameter log-logistic IC50 estimation, Kaplan-Meier/log-rank survival comparisons, and linear regression, with P < .05 considered significant.
Limitations
- Stated: orthotopic PDXs are limited as BBB models because they are smaller, show varying infiltration into normal brain, and typically lack the proliferative vasculature of human GBM, so BBB disruption is less heterogeneous than in patients.
- Stated: siRNA did not achieve sufficient MDM2 knockdown to validate the accumulation mechanism; recurrent tumors were not evaluated for TP53 mutation; the free-fraction target-concentration approach depends on accurate free-fraction measurement and does not account for treatment duration or genotype-related variability.
- Evident from the text: murine p53-MDM2 is insensitive to existing MDM2 inhibitors, so mouse exposures may exceed clinically achievable levels due to human toxicity; PK/PD sampling used a single 24-hour timepoint; gene expression analyses showed high variability across replicates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
13 Valid · 0 Not valid · 12 Not checked · 101 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Drug efflux pumps active within brain capillary endothelial cells further limit the delivery of MDM2 inhibitors into tumor regions with a relatively intact BBB.17 , 26”
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Discussion
What the sources say
- Not checked — no full text of the sourcecites [17] Vaubel, 2025, Preclinical modeling of navtemadlin pharmacokinetics, pharmacodynamics, and efficacy in IDH-wild-type glioblastoma, Clin Cancer Res doi:10.1158/1078-0432.ccr-25-024440591434
- Supportedcites [26] Zhang, 2023, How much is enough? Impact of efflux transporters on drug delivery leading to efficacy in the treatment of brain tumors, Pharm Res source
The Introduction states that BBB efflux transporters on endothelial cells hinder anticancer-drug entry into brain tumors. It specifically reports that the MDM2 inhibitor SAR405838 is transported out of the brain by P-gp and that disrupting an intact BBB improved its efficacy in an orthotopic tumor model. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“P53 drives transcription of numerous target genes, which provide a mechanism-based PD biomarker for MDM2 inhibitor therapy.18”
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Discussion
What the sources say
- Partly supportedcites [18] Fischer, 2017, Census and evaluation of p53 target genes, Oncogene sourceExperimental — accuracy not yet measured
The ‘Evaluating reproducibility’ section identifies 343 high-confidence p53-activated target genes, and ‘Feedback regulation’ describes MDM2 as a p53 target gene. The paper does not establish that expression of those genes serves as a pharmacodynamic biomarker for MDM2 inhibitor therapy (searched: pharmacodynamic, biomarker, and MDM2 inhibition). (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brigimadlin monotherapy increased survival relative to vehicle (61 vs 40 days, P = .02)”
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Results > Impact of BBB Efflux on Efficacy in Orthotopic PDX
plainstates a causen = 5 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While GBM108 (MDM2-amplified) was the most sensitive model in vitro”
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Results > Effects of Brigimadlin In Vitro
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the TP53-mutant GBM120 model was highly resistant to brigimadlin.”
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Results > Effects of Brigimadlin In Vitro
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
71 more claims
Create a free account to see all 126 claims and every source verdict.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 47
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Discussion
“brigimadlin combined with fractionated RT extended survival in 2 MDM2-amplified PDXs and to a lesser extent in 1 of 2 MDM2 non-amplified PDXs (Figure 4).”
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Results > Combination of Brigimadlin and RT
“Figure: Figure 5. Efficacy of brigimadlin ± radiotherapy in orthotopic PDX.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Discussion
“modest but significant differences in drug levels were noted in the untreated MDM2-amplified vs non-amplified lines, but this difference was significantly accentuated after 6 hours”
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Results > Intracellular Accumulation of Brigimadlin in MDM2-Amplified GBM
“explant cultures from GBM14, GBM108, and GBM143 were treated with 30 nmol/L brigimadlin for 0.5 or 6 hours, then MDM2 expression and intracellular drug levels were evaluated by Western blot and LC-MS/MS, respectively (Figure 3).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Methods > Subcutaneous PDX
“For evaluation of brigimadlin efficacy, mice (n = 5 per group) were randomized to treatment with vehicle or brigimadlin (0.125, 0.25, 0.5, 1, or 2 mg/kg) weekly by oral gavage”
§ Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts > Results > PK, PD, and Efficacy of Brigimadlin in Subcutaneous PDXs
“Mice with subcutaneous GBM108, GBM143, or GBM14 tumors were randomized to treatment with vehicle or brigimadlin (0.125, 0.25, 0.5, 1, or 2 mg/kg) weekly for 4 weeks (n = 5-6 per group).”
Citations
Cites
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Self-citationKastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Cell-to-cell variation in p53 dynamics leads to fractional killing.
Paek, A. L., Liu, J. C., Loewer, A., Forrester, W. C., & Lahav, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.025 · Cited by 292
Vaubel, R. A., Tian, S., Remonde, D., Schroeder, M. A., Mladek, A. C., Kitange, G. J., Caron, A., Kollmeyer, T. M., Grove, R., Peng, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0909 · Cited by 227
Self-citationCarlson, B. L., Pokorny, J. L., Schroeder, M. A., & Sarkaria, J. N. (2011) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1416s52 · Cited by 227
Self-citationWong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Metadata
- Authors
- Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., Hu, Z., Ott, L. L., Carlson, B. L., Bakken, K. K., Pasa, T., Sarkaria, N. R., Talele, S., Eckel-Passow, J. E., Sini, P., Elmquist, W. F., & Sarkaria, J. N.
- Affiliations
- Mayo Clinic (US)
- University of Minnesota (US)
- Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN,
- Boehringer Ingelheim (Austria) (AT)
- Corresponding author
- Sarkaria, Jann N
- ORCID
- Venue
- Neuro-Oncology Advances
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-12-15
- Volume
- 8
- Issue
- 1
- Pages
- vdaf259-vdaf259
- ISSN
- 2632-2498 (ISSN-L)
- PMC
- PMC12883205
- OpenAlex
- W4417413993
- Cited by
- 0
- References
- 29
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuro-Oncology Advances (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- Funders
- Boehringer Ingelheim, National Institutes of Health/National Cancer Institute (U19-CA264362)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- brigimadlin, MDM2 inhibitors, glioblastoma, patient-derived xenografts, MDM2 amplification, p53 reactivation, pharmacokinetics, pharmacodynamics, intratumoral drug accumulation, fractionated irradiation, orthotopic xenograft, tumor regrowth, p53 target genes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. https://app.cochat.ai/papers/10.1093/noajnl/vdaf259
- The paper
- Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., Hu, Z., Ott, L. L., Carlson, B. L., Bakken, K. K., Pasa, T., Sarkaria, N. R., Talele, S., Eckel-Passow, J. E., Sini, P., . . . Sarkaria, J. N. (2026). Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdaf259
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.